Three enzymatic pathways of arachidonic acid metabolism, involving cyclooxygenases, lipoxygenases, and cytochrome P450 epoxygenases, have been identified in mammalian cells, but only the first two have been linked to human cancer. The HIV protease inhibitor, ritonavir, is a potent inhibitor of epoxygenases that arrests the growth of breast cancer xenografts, but its mechanism of action is unknown. Epoxygenases promote the production of epoxyeicosatrienoic acids (EET's) that activate Akt kinase. This project seeks to determine whether epoxygenases are cancer therapeutic targets. The hypothesis to be tested is that epoxygenase activation promotes breast cancer progression by promoting Akt phosphorylation and cancer cell survival.
The specific aims are: 1. To establish the molecular mechanisms by which epoxygenases cause growth dysregulation in breast cancer, 2. To establish that epoxygenases enhance the oncogenic potential of the Ha-ras oncogene in mammary carcinoma. 3. To establish that the epoxygenase pathway activates and requires Hsp90 for cancer cell survival. Targeted lipidomics using the method of electron capture APCI-MS/MS will be used to profile EET regio- and stereoisomers. A bacterial epoxygenase will be tested for cooperation with activated Ha-ras in breast cancer progression. These studies will promote further development of epoxygenases as targets for breast cancer therapeutics. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA113570-02
Application #
7128186
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Poland, Alan P
Project Start
2005-09-30
Project End
2006-08-26
Budget Start
2006-08-25
Budget End
2006-08-26
Support Year
2
Fiscal Year
2006
Total Cost
$5,206
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Guo, Zhijun; Johnson, Veronica; Barrera, Jaime et al. (2018) Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them. Cancer Metastasis Rev 37:409-423
Guo, Zhijun; Sevrioukova, Irina F; Denisov, Ilia G et al. (2017) Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria. Cell Chem Biol 24:1259-1275.e6
Grossmann, Michael E; Yang, Da-Qing; Guo, Zhijun et al. (2015) Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis. Curr Pharmacol Rep 1:312-323
Rodriguez, Mariangellys; Potter, David A (2013) CYP1A1 regulates breast cancer proliferation and survival. Mol Cancer Res 11:780-92
Potter, David A; Yee, Douglas; Guo, Zhijun et al. (2012) Should diabetic women with breast cancer have their own intervention studies? Endocr Relat Cancer 19:C13-7
Mitra, Ranjana; Guo, Zhijun; Milani, Monica et al. (2011) CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem 286:17543-59
Srirangam, Anjaiah; Milani, Monica; Mitra, Ranjana et al. (2011) The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. J Thorac Oncol 6:661-70
Mitra, Ranjana; Lee, Jinseon; Jo, Jisuk et al. (2011) Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model. Clin Cancer Res 17:2934-46
Milani, Monica; Jha, Gautam; Potter, David A (2009) Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Clin Med Ther 1:141-156
Yamoutpour, Farnaz; Bodempudi, Vidya; Park, Shay E et al. (2008) Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther 7:3586-97

Showing the most recent 10 out of 12 publications